NovoCure (NVCR) Competitors $16.86 +0.38 (+2.31%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NVCR vs. IRTC, NVRO, BLCO, INSP, PRCT, AXNX, NVST, NARI, TMDX, and LIVNShould you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include iRhythm Technologies (IRTC), Nevro (NVRO), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Axonics (AXNX), Envista (NVST), Inari Medical (NARI), TransMedics Group (TMDX), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. NovoCure vs. iRhythm Technologies Nevro Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Axonics Envista Inari Medical TransMedics Group LivaNova iRhythm Technologies (NASDAQ:IRTC) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations. Do analysts recommend IRTC or NVCR? iRhythm Technologies currently has a consensus price target of $108.50, suggesting a potential upside of 47.14%. NovoCure has a consensus price target of $26.17, suggesting a potential upside of 55.20%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than iRhythm Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRhythm Technologies 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media favor IRTC or NVCR? In the previous week, iRhythm Technologies had 4 more articles in the media than NovoCure. MarketBeat recorded 6 mentions for iRhythm Technologies and 2 mentions for NovoCure. iRhythm Technologies' average media sentiment score of 1.06 beat NovoCure's score of 0.67 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IRTC or NVCR more profitable? NovoCure has a net margin of -25.93% compared to iRhythm Technologies' net margin of -26.90%. NovoCure's return on equity of -41.48% beat iRhythm Technologies' return on equity.Company Net Margins Return on Equity Return on Assets iRhythm Technologies-26.90% -120.86% -17.96% NovoCure -25.93%-41.48%-12.74% Do institutionals and insiders believe in IRTC or NVCR? 84.6% of NovoCure shares are held by institutional investors. 0.7% of iRhythm Technologies shares are held by company insiders. Comparatively, 6.3% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable valuation and earnings, IRTC or NVCR? iRhythm Technologies has higher earnings, but lower revenue than NovoCure. iRhythm Technologies is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiRhythm Technologies$492.68M4.68-$123.41M-$4.86-15.17NovoCure$509.34M3.58-$207.04M-$1.40-12.04 Does the MarketBeat Community believe in IRTC or NVCR? NovoCure received 69 more outperform votes than iRhythm Technologies when rated by MarketBeat users. However, 66.17% of users gave iRhythm Technologies an outperform vote while only 63.61% of users gave NovoCure an outperform vote. CompanyUnderperformOutperformiRhythm TechnologiesOutperform Votes40366.17% Underperform Votes20633.83% NovoCureOutperform Votes47263.61% Underperform Votes27036.39% Which has more risk & volatility, IRTC or NVCR? iRhythm Technologies has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. SummaryNovoCure beats iRhythm Technologies on 10 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCR vs. The Competition Export to ExcelMetricNovoCureSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.82B$4.41B$5.04B$8.81BDividend YieldN/A41.16%5.16%4.07%P/E Ratio-12.0424.83130.5317.82Price / Sales3.5847.021,183.8674.55Price / CashN/A51.8733.6132.53Price / Book4.974.974.684.68Net Income-$207.04M$13.76M$119.23M$226.08M7 Day Performance1.75%-1.08%-1.83%-1.04%1 Month Performance3.63%0.58%-3.61%1.04%1 Year Performance37.86%50.91%31.74%26.28% NovoCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCRNovoCure3.7354 of 5 stars$16.86+2.3%$26.17+55.2%+38.3%$1.78B$509.34M-12.041,453IRTCiRhythm Technologies3.2627 of 5 stars$73.74-2.3%$108.50+47.1%-11.8%$2.31B$492.68M-15.172,000NVRONevro2.9004 of 5 stars$4.23-0.2%$9.10+115.1%-74.5%$158.88M$425.17M0.001,215Analyst UpgradeGap DownBLCOBausch + Lomb2.7887 of 5 stars$19.39-0.8%$20.91+7.8%+23.2%$6.83B$4.68B-18.4713,300INSPInspire Medical Systems4.91 of 5 stars$184.88+5.0%$233.58+26.3%+29.2%$5.54B$624.80M172.781,011Analyst UpgradePositive NewsGap UpPRCTPROCEPT BioRobotics1.5836 of 5 stars$92.70-0.9%$89.50-3.5%+180.7%$4.88B$136.19M0.00626AXNXAxonics3.2556 of 5 stars$70.98flat$71.00+0.0%N/A$3.63B$366.38M-591.45610News CoverageNVSTEnvista3.8665 of 5 stars$20.37+0.5%$20.71+1.7%-14.3%$3.49B$2.57B0.0012,800NARIInari Medical3.255 of 5 stars$49.00-3.9%$58.89+20.2%-15.9%$2.87B$574.50M-36.301,300Insider TradePositive NewsTMDXTransMedics Group4.4357 of 5 stars$77.20-6.9%$131.80+70.7%+10.5%$2.78B$241.62M82.13210Analyst ForecastGap DownLIVNLivaNova4.3678 of 5 stars$50.05-2.6%$69.17+38.2%+6.8%$2.72B$1.15B122.292,900 Related Companies and Tools Related Companies iRhythm Technologies Alternatives Nevro Alternatives Bausch + Lomb Alternatives Inspire Medical Systems Alternatives PROCEPT BioRobotics Alternatives Axonics Alternatives Envista Alternatives Inari Medical Alternatives TransMedics Group Alternatives LivaNova Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NVCR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.